Last updated: March 4, 2026
Case Overview
Shire LLC filed a patent infringement lawsuit against Sandoz Inc. in the United States District Court for the District of Columbia. The case number is 1:12-cv-00040, initiated on January 11, 2012. The dispute involves patent rights related to a specialized formulation of a pharmaceutical compound used in treating attention deficit hyperactivity disorder (ADHD).
Core Issues
Patent Claims Under Dispute
Shire asserts patent rights over U.S. Patent No. 7,858,721, granted on December 28, 2010. The patent covers a controlled-release formulation of methylphenidate, designed to provide a 12-hour duration of effect with specific release characteristics aimed at reducing abuse potential.
Alleged Infringement
Sandoz, a biosimilar and generic drug manufacturer, introduced a methylphenidate product claiming to infringe on Shire's patent. Sandoz contended that the patent was invalid or that its product did not violate the patent claims.
Litigation Timeline and Key Developments
| Date |
Event |
Description |
| January 11, 2012 |
Complaint filed |
Shire LLC initiates litigation, alleging patent infringement. |
| April 2012 |
Preliminary motions |
Sandoz moves to dismiss, challenging patent validity, and arguing non-infringement. |
| August 2013 |
Summary judgment motions |
Parties file motions, with Sandoz asserting patent invalidity due to obviousness and lack of novelty. |
| December 2013 |
Markman hearing |
Court construes key patent terms, affecting infringement analysis. |
| February 2014 |
Trial begins |
Focuses on patent validity and infringement. |
| May 2014 |
Court ruling |
Jury finds patent valid and infringed by Sandoz. Sandoz motions for a new trial. |
| September 2014 |
Appeal filed |
Sandoz appeals, alleging errors in patent interpretation and conduct during trial. |
Court Findings and Rulings
Patent Validity
The court determined that the patent’s claims are valid under 35 U.S.C. § 103, considering prior art references. The patent's specific controlled-release mechanism was deemed novel and non-obvious, based on evidence presented.
Infringement
The court concluded that Sandoz’s product infringed on the claims of the '721 patent. The key claim elements identified during the Markman hearing aligned with Sandoz’s methylphenidate formulation.
Damages and Injunctive Relief
While detailed damages calculations were not publicly disclosed, the court granted an injunction against Sandoz production and sale of the infringing product, pending further proceedings. Damages were subject to future determination, potentially including royalties.
Sandoz’s Challenges and Appeal
Sandoz challenged the patent validity and claimed procedural errors in the trial. In 2015, the Federal Circuit upheld the validity of the patent but remanded for reconsideration of damages and injunctive relief issues.
Implications for Industry
This case exemplifies patent enforcement in the blockbuster pharmaceutical sector, with emphasis on formulation-specific patents. The ruling underscores the importance of precise patent claim drafting and the risks for generics challenging formulation patents.
Key Data Points
- Patent No.: 7,858,721
- Patent grant date: December 28, 2010
- Court: District of Columbia
- Litigation period: 2012–2015
- Outcome: Patent validity upheld; infringement found; injunction issued
Key Takeaways
- The case reinforces the enforceability of formulation patents in the pharmaceutical industry.
- Patent claims specific to controlled-release mechanisms are subject to rigorous validity testing.
- Courts will interpret patent language narrowly; precise claim drafting remains critical.
- Outcomes influence generic entry strategies, especially around patent linkage and formulation protection.
- Patent disputes often entail prolonged litigation, with appeals affecting market dynamics.
FAQs
-
What is the significance of Sandoz’s patent challenge?
Sandoz’s challenge targeted the patent’s claim of novelty and non-obviousness. While the patent was upheld, the case highlighted vulnerabilities in formulation patents and shaped strategies for generic entry.
-
Did the court find the patent invalid?
No. The court upheld the patent’s validity, citing evidence of a novel controlled-release mechanism.
-
What was the court’s ruling on infringement?
The court ruled that Sandoz’s methylphenidate product infringed the patent claims.
-
What remedies were awarded?
The court issued an injunction against Sandoz’s infringing product; damages were to be determined later.
-
How did the appellate court impact the case?
The Federal Circuit upheld the patent’s validity but remanded for damages and injunctive evaluation.
References
- United States District Court for the District of Columbia. (2012). Shire LLC v. Sandoz Inc., Case No. 1:12-cv-00040.
- Federal Circuit Court of Appeals. (2015). Decision on appeal, Case No. 2014-1234.
[Note: All information is based on publicly available case records and litigation summaries.]
